

## Actions Taken by FDA Center for Veterinary Medicine

---

The following corrections or additions to the January 2000 list were published in the Federal Register in May 2000.

### Supplemental Approvals

---

**ANADA Number: 200-221**

**This supplemental application provides for subcutaneous use of a cattle ear implant for pasture cattle for increased rate of weight gain. Technical changes are also made.**

Trade Name: Component<sup>®</sup> TE-G  
Ingredients: Trenbolone acetate, estradiol  
Sponsor: Ivy Laboratories, Division of Ivy Animal Health, Inc.  
Approval Date: March 6, 2000  
Status: Over-the-counter  
Route: Subcutaneous  
Species: Cattle  
Drug Form: Implant  
Concentration: 40 mg trenbolone acetate, 8 mg estradiol  
Indications: For increased rate of weight gain in pasture cattle (slaughter, stocker, and feeder steers and heifers).  
Tolerance: 21CFR 556.240: Estradiol: Residues for estradiol and related esters may not exceed the following increments above the concentrations of estradiol naturally present in the untreated animals; in the uncooked edible tissues of heifers, steers, and calves: 120 parts per trillion (ppt) for muscle, 480 ppt in fat, 360 ppt for kidney, and 240 ppt for liver.  
21CFR 556.739: Trenbolone: A tolerance for total trenbolone residues in uncooked edible tissues of cattle is not needed. The ADI of 0.0004 milligram per kilogram of body weight per day has been established.  
Withdrawal: Zero days

*21CFR 522.2477*

### Change of Sponsor Name and Address

---

From: Global Pharmaceutical Corp.  
Castor and Kensington Aves.  
Philadelphia, PA 19124  
Labeler code: 000115

To: IMPAX Laboratories, Inc.  
30831 Huntwood Ave.  
Hayward, CA 94544

### Suitability Petition Action

---

Number: 00P-0596/CP1  
Sponsor: Phoenix Scientific, Inc.  
Petition: Request permission to file an ANADA for a generic new animal drug, phenylbutazone, which differs from the pioneer product, phenylbutazone (Phoenix Scientific, Inc.), NADA 091-818, by the following characteristic: The generic product will consist of a different physical form, powder, whereas the pioneer approved product is a tablet.  
Action: Not required (denied on) May 5, 2000.